English

Cocrystal Pharma, Inc.

EDGAR

COCP Quarterly report (10-Q) · filed 2026-08-13

103 filing records in this dataset, filed from 2007-11-09 to 2026-08-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

105 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 105000 USD Source

Operating margin

-3,032.38%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -3184000 USD Source
Revenue: 105000 USD Source

Operating cash flow

-2.52 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -4856000 USD Source
Operating Cash Flow: -2340000 USD Source

Cash and cash equivalents: 7.03 million USD 2025-12-31 Source
Exact value

7025000 USD
Long-term debt including current maturities: 49.9 million USD 2015-12-31 Source
Exact value

49936000 USD
Shares outstanding: 13.8 million shares 2026-06-30 Source
Exact value

13789000 shares

Reported share-count change

35.53% · 3.62 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

10174000 shares · 2025-06-30· Source
13789000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-9.91 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -2049000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -8800000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -6405000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -2299000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -3164000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-7.96 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -6456000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5094000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -8200000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -6456000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2340000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -4856000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2340000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2020-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2015-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 8.7 million

Prior period

−USD 17.5 million

2024-01-01 – 2024-12-31
Current period

−USD 8.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-8800000 − -17504000 = 8704000 USD

-17504000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-8800000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Year-over-year change in Net income: 8704000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -8800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#824843 Filing: 000149315226013838 Input fundies:NetIncome: -17504000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#795093 Filing: 000149315226013838
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 8.29 million

Prior period

−USD 16.49 million

2024-01-01 – 2024-12-31
Current period

−USD 8.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-8200000 − -16485000 = 8285000 USD

-16485000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-8200000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Year-over-year change in Operating cash flow: 8285000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -8200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#825271 Filing: 000149315226013838 Input fundies:OperatingCashFlow: -16485000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#805163 Filing: 000149315226013838
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+50%

Prior period

USD 8,000

2024-01-01 – 2024-12-31
Current period

USD 12,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

12000 − 8000 = 4000 USD

8000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
12000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Year-over-year change in Capital expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#806771 Filing: 000149315226013838 Input fundies:CapitalExpenditure: 8000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#807229 Filing: 000149315226013838
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 2.01 million 100% of revenue
Operating costs Derived USD 11.6 million 576% of revenue
Operating income −USD 9.59 million −476% of revenue
Tax, interest and other Derived USD 62,000 3.1% of revenue
Net income −USD 9.65 million −479% of revenue

Cash

Operating cash flow −USD 9.83 million −488% of revenue
Capital expenditure USD 240,000 12% of revenue
Free cash flow Derived −USD 10.07 million −500% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 837% of revenue.
2020 Operating loss: operating costs were 576% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	6564000	54970000 Derived	-48406000	-237000 Derived	-48169000	-1708000 Derived	Source 2019-01-01 – 2019-12-31: 6564000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -48406000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -48169000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -1563000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 145000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	2014000	11600000 Derived	-9586000	62000 Derived	-9648000	-10070000 Derived	Source 2020-01-01 – 2020-12-31: 2014000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -9586000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -9648000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -9830000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 240000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	6564000	Revenue: 6564000 Open source
20202020-12-31	Revenue	2014000	Revenue: 2014000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-69.3% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 6564000 Open source
20202020-12-31	Year over year	-69.3%	Revenue: 2014000 Open source Revenue: 6564000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -476% 2020

Net margin -479% 2020

Free cash flow margin -500% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-737.4%	Operating Income: -48406000 Open source Revenue: 6564000 Open source
20202020-12-31	Operating margin	-476%	Operating Income: -9586000 Open source Revenue: 2014000 Open source
20192019-12-31	Net margin	-733.8%	Net Income: -48169000 Open source Revenue: 6564000 Open source
20202020-12-31	Net margin	-479%	Net Income: -9648000 Open source Revenue: 2014000 Open source
20192019-12-31	Free cash flow margin	-26%	Revenue: 6564000 Open source Operating Cash Flow: -1563000 Open source Capital Expenditure: 145000 Open source
20202020-12-31	Free cash flow margin	-500%	Revenue: 2014000 Open source Operating Cash Flow: -9830000 Open source Capital Expenditure: 240000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -9.8M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-1563000	Operating Cash Flow: -1563000 Open source
20202020-12-31	Operating cash flow	-9830000	Operating Cash Flow: -9830000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -10.1M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-1708000	Operating Cash Flow: -1563000 Open source Capital Expenditure: 145000 Open source
20202020-12-31	Free cash flow	-10070000	Operating Cash Flow: -9830000 Open source Capital Expenditure: 240000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

3.2% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	9.9%	Total Liabilities: 2823000 Open source Total Assets: 28531000 Open source
20202020-12-31	Liabilities / assets	3.2%	Total Liabilities: 1737000 Open source Total Assets: 54242000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

25.05× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	3.62×	Current Assets: 8281000 Open source Current Liabilities: 2286000 Open source
20202020-12-31	Current assets / current liabilities	25.05×	Current Assets: 34015000 Open source Current Liabilities: 1358000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 74.87 million Exact value Exact value: -74874000 USD 2016-01-01 – 2016-12-31: -74874000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2016-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -74874000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74874000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315218003708/cocp-20171231.xml#125829 Filing: 000149315218003708 The citation records this snapshot. The page link may show a newer release later.	−USD 14.66 million Exact value Exact value: -14655000 USD 2016-01-01 – 2016-12-31: -14655000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2016-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -14655000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14655000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315218003708/cocp-20171231.xml#411015 Filing: 000149315218003708 The citation records this snapshot. The page link may show a newer release later.	USD 51,000 Exact value Exact value: 51000 USD 2016-01-01 – 2016-12-31: 51000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2016-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 51000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315218003708/cocp-20171231.xml#410459 Filing: 000149315218003708 The citation records this snapshot. The page link may show a newer release later.	−USD 14.71 million Calculation and evidence -14655000 − 51000 USD Exact free cash flow: -14706000 USD 2016-01-01 – 2016-12-31: -14655000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 51000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2016-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -14706000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14655000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315218003708/cocp-20171231.xml#411015 Filing: 000149315218003708 Input fundies:CapitalExpenditure: 51000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315218003708/cocp-20171231.xml#410459 Filing: 000149315218003708 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 613,000 Exact value Exact value: -613000 USD 2017-01-01 – 2017-12-31: -613000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2017-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -613000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -613000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315219004386/cocp-20181231.xml#98458 Filing: 000149315219004386 The citation records this snapshot. The page link may show a newer release later.	−USD 6.9 million Exact value Exact value: -6903000 USD 2017-01-01 – 2017-12-31: -6903000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2017-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -6903000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6903000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315219004386/cocp-20181231.xml#151980 Filing: 000149315219004386 The citation records this snapshot. The page link may show a newer release later.	USD 40,000 Exact value Exact value: 40000 USD 2017-01-01 – 2017-12-31: 40000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2017-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 40000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 40000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315219004386/cocp-20181231.xml#152349 Filing: 000149315219004386 The citation records this snapshot. The page link may show a newer release later.	−USD 6.94 million Calculation and evidence -6903000 − 40000 USD Exact free cash flow: -6943000 USD 2017-01-01 – 2017-12-31: -6903000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 40000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2017-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -6943000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6903000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315219004386/cocp-20181231.xml#151980 Filing: 000149315219004386 Input fundies:CapitalExpenditure: 40000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315219004386/cocp-20181231.xml#152349 Filing: 000149315219004386 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 49.05 million Exact value Exact value: -49048000 USD 2018-01-01 – 2018-12-31: -49048000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2018-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -49048000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49048000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/cocp-20191231.xml#112581 Filing: 000149315220004916 The citation records this snapshot. The page link may show a newer release later.	−USD 8.29 million Exact value Exact value: -8290000 USD 2018-01-01 – 2018-12-31: -8290000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2018-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -8290000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8290000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/cocp-20191231.xml#664557 Filing: 000149315220004916 The citation records this snapshot. The page link may show a newer release later.	USD 28,000 Exact value Exact value: 28000 USD 2018-01-01 – 2018-12-31: 28000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2018-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 28000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 28000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/cocp-20191231.xml#664927 Filing: 000149315220004916 The citation records this snapshot. The page link may show a newer release later.	−USD 8.32 million Calculation and evidence -8290000 − 28000 USD Exact free cash flow: -8318000 USD 2018-01-01 – 2018-12-31: -8290000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 28000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2018-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -8318000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8290000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/cocp-20191231.xml#664557 Filing: 000149315220004916 Input fundies:CapitalExpenditure: 28000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/cocp-20191231.xml#664927 Filing: 000149315220004916 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 48.17 million Exact value Exact value: -48169000 USD 2019-01-01 – 2019-12-31: -48169000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2019-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -48169000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48169000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315221006211/cocp-20201231.xml#161619 Filing: 000149315221006211 The citation records this snapshot. The page link may show a newer release later.	−USD 1.56 million Exact value Exact value: -1563000 USD 2019-01-01 – 2019-12-31: -1563000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2019-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -1563000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1563000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315221006211/cocp-20201231.xml#164434 Filing: 000149315221006211 The citation records this snapshot. The page link may show a newer release later.	USD 145,000 Exact value Exact value: 145000 USD 2019-01-01 – 2019-12-31: 145000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2019-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 145000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 145000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315221006211/cocp-20201231.xml#167200 Filing: 000149315221006211 The citation records this snapshot. The page link may show a newer release later.	−USD 1.71 million Calculation and evidence -1563000 − 145000 USD Exact free cash flow: -1708000 USD 2019-01-01 – 2019-12-31: -1563000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 145000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2019-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -1708000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1563000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315221006211/cocp-20201231.xml#164434 Filing: 000149315221006211 Input fundies:CapitalExpenditure: 145000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315221006211/cocp-20201231.xml#167200 Filing: 000149315221006211 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 9.65 million Exact value Exact value: -9648000 USD 2020-01-01 – 2020-12-31: -9648000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2020-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -9648000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9648000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/form10-k.htm#891624 Filing: 000149315222007551 The citation records this snapshot. The page link may show a newer release later.	−USD 9.83 million Exact value Exact value: -9830000 USD 2020-01-01 – 2020-12-31: -9830000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2020-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -9830000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9830000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/form10-k.htm#869380 Filing: 000149315222007551 The citation records this snapshot. The page link may show a newer release later.	USD 240,000 Exact value Exact value: 240000 USD 2020-01-01 – 2020-12-31: 240000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2020-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 240000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 240000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/form10-k.htm#871446 Filing: 000149315222007551 The citation records this snapshot. The page link may show a newer release later.	−USD 10.07 million Calculation and evidence -9830000 − 240000 USD Exact free cash flow: -10070000 USD 2020-01-01 – 2020-12-31: -9830000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 240000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2020-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -10070000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9830000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/form10-k.htm#869380 Filing: 000149315222007551 Input fundies:CapitalExpenditure: 240000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315222007551/form10-k.htm#871446 Filing: 000149315222007551 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 14.19 million Exact value Exact value: -14185000 USD 2021-01-01 – 2021-12-31: -14185000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2021-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -14185000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14185000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315223009385/form10-k.htm#943386 Filing: 000149315223009385 The citation records this snapshot. The page link may show a newer release later.	−USD 12.72 million Exact value Exact value: -12719000 USD 2021-01-01 – 2021-12-31: -12719000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2021-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -12719000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12719000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315223009385/form10-k.htm#969341 Filing: 000149315223009385 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2021-01-01 – 2021-12-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2021-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315223009385/form10-k.htm#974495 Filing: 000149315223009385 The citation records this snapshot. The page link may show a newer release later.	−USD 12.77 million Calculation and evidence -12719000 − 52000 USD Exact free cash flow: -12771000 USD 2021-01-01 – 2021-12-31: -12719000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2021-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -12771000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12719000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315223009385/form10-k.htm#969341 Filing: 000149315223009385 Input fundies:CapitalExpenditure: 52000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315223009385/form10-k.htm#974495 Filing: 000149315223009385 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 38.84 million Exact value Exact value: -38837000 USD 2022-01-01 – 2022-12-31: -38837000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2022-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -38837000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38837000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011613/form10-k.htm#847258 Filing: 000149315224011613 The citation records this snapshot. The page link may show a newer release later.	−USD 21.44 million Exact value Exact value: -21435000 USD 2022-01-01 – 2022-12-31: -21435000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2022-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -21435000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21435000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011613/form10-k.htm#872935 Filing: 000149315224011613 The citation records this snapshot. The page link may show a newer release later.	USD 74,000 Exact value Exact value: 74000 USD 2022-01-01 – 2022-12-31: 74000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2022-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 74000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 74000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011613/form10-k.htm#878236 Filing: 000149315224011613 The citation records this snapshot. The page link may show a newer release later.	−USD 21.51 million Calculation and evidence -21435000 − 74000 USD Exact free cash flow: -21509000 USD 2022-01-01 – 2022-12-31: -21435000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 74000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2022-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -21509000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21435000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011613/form10-k.htm#872935 Filing: 000149315224011613 Input fundies:CapitalExpenditure: 74000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315224011613/form10-k.htm#878236 Filing: 000149315224011613 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 17.98 million Exact value Exact value: -17984000 USD 2023-01-01 – 2023-12-31: -17984000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2023-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -17984000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17984000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm#777716 Filing: 000164117225001496 The citation records this snapshot. The page link may show a newer release later.	−USD 14.67 million Exact value Exact value: -14666000 USD 2023-01-01 – 2023-12-31: -14666000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2023-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -14666000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14666000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm#787552 Filing: 000164117225001496 The citation records this snapshot. The page link may show a newer release later.	USD 118,000 Exact value Exact value: 118000 USD 2023-01-01 – 2023-12-31: 118000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2023-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 118000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 118000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm#789617 Filing: 000164117225001496 The citation records this snapshot. The page link may show a newer release later.	−USD 14.78 million Calculation and evidence -14666000 − 118000 USD Exact free cash flow: -14784000 USD 2023-01-01 – 2023-12-31: -14666000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 118000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2023-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -14784000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14666000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm#787552 Filing: 000164117225001496 Input fundies:CapitalExpenditure: 118000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000164117225001496/form10-k.htm#789617 Filing: 000164117225001496 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 17.5 million Exact value Exact value: -17504000 USD 2024-01-01 – 2024-12-31: -17504000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2024-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -17504000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17504000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#795093 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	−USD 16.49 million Exact value Exact value: -16485000 USD 2024-01-01 – 2024-12-31: -16485000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2024-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -16485000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16485000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#805163 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	USD 8,000 Exact value Exact value: 8000 USD 2024-01-01 – 2024-12-31: 8000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2024-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 8000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#807229 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	−USD 16.49 million Calculation and evidence -16485000 − 8000 USD Exact free cash flow: -16493000 USD 2024-01-01 – 2024-12-31: -16485000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 8000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2024-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -16493000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16485000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#805163 Filing: 000149315226013838 Input fundies:CapitalExpenditure: 8000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#807229 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 8.8 million Exact value Exact value: -8800000 USD 2025-01-01 – 2025-12-31: -8800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Net Income: -8800000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#824843 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	−USD 8.2 million Exact value Exact value: -8200000 USD 2025-01-01 – 2025-12-31: -8200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Operating Cash Flow: -8200000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#825271 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2025-01-01 – 2025-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#806771 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.	−USD 8.21 million Calculation and evidence -8200000 − 12000 USD Exact free cash flow: -8212000 USD 2025-01-01 – 2025-12-31: -8200000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cocrystal Pharma, Inc. · 2025-12-31 Cocrystal Pharma, Inc. (edgar:1412486) Free cash flow: -8212000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1412486?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8200000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#825271 Filing: 000149315226013838 Input fundies:CapitalExpenditure: 12000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1412486/000149315226013838/form10-k.htm#806771 Filing: 000149315226013838 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

103 filings · 3,457 latest values · 3,457 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001412486, 1412486, COCP, edgar:1412486

Also known as BIOZONE PHARMACEUTICALS, INC., COCRYSTAL PHARMA, INC., Cocrystal Pharma, Inc., Cocrystal Pharma, Inc., International Surf Resorts, Inc.

Cocrystal Pharma, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation